Indeed, only eight out of 26 (31%) MITFlow/PTENnegative (MITFlow/PTENneg) melanomas had tumor-associated CD8+ T-cells, while the corresponding results for MITFhigh/PTENpositive (MITFhigh/PTENpos) melanomas were 38 out of 53 (72%) (Figure 2B). The gene discussed is CD8A; the disease is neoplasm.